Clinical Trials Browser

NCT06496178 2026-03-18

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

Phase 3 Recruiting

500 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06589804 2026-03-18

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Phase 3 Recruiting

158 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT04892173 2026-03-13

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Phase 3 Recruiting

500 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06992427 2026-03-04

HOPE

Phase 3 Recruiting

228 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07026474 2026-03-02

RePaIr-HN

Phase 3 Recruiting

214 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06525220 2026-02-23

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Phase 3 Recruiting

500 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT07333274 2026-01-12

Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Phase 3 Recruiting

335 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06699212 2025-10-15

ECLIPSE

Phase 3 Recruiting

412 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06256588 2025-09-25

JADE

Phase 3 Recruiting

864 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06492460 2025-08-14

2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma

Phase 3 Recruiting

422 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06064877 2025-04-13

FIERCE-HN

Phase 3 Recruiting

410 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasm Metastasis, Recurrence

NCT06258811 2025-03-13

Neoadjuvant Immunochemotherapy for LAOSCC

Phase 3 Recruiting

134 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04747054 2024-10-26

PembroMetaRT

Phase 3 Recruiting

102 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, Neoplasm Metastasis

NCT06248996 2024-09-19

ARTSCAN VI

Phase 3 Recruiting

308 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05798793 2024-04-02

NEOPCOSCC

Phase 3 Recruiting

309 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06102395 2023-10-30

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Phase 3 Recruiting

272 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05980715 2023-08-08

HNC-SYSU-003

Phase 3 Recruiting

324 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05044117 2022-03-03

Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)

Phase 3 Recruiting

220 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck